DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dendrid (Idoxuridine Ophthalmic) - Summary

 
 



DENDRID SUMMARY

DENDRID®
(idoxuridine)
Sterile Ophthalmic Solution

Dendrid® (idoxuridine) is an antiviral chemotherapeutic agent prepared in a sterile buffered isotonic solution.

DENDRID (idoxuridine OPHTHALMIC) is indicated for the following:

For the treatment of keratitis caused by the virus of herpes simplex.


See all Dendrid indications & dosage >>

NEWS HIGHLIGHTS

Clinical Trials Related to Dendrid (Idoxuridine Ophthalmic)

PET Scans in Patients With Locally Advanced Breast Cancer [Completed]
RATIONALE: Imaging procedures such as PET scans may improve the ability to monitor the effectiveness of chemotherapy for locally advanced breast cancer. PURPOSE: This clinical trial is studying how well PET scans work in patients with locally advanced breast cancer who will undergo chemotherapy.

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia [Active, not recruiting]
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.

IUdR/BUdR Cell Cycle Labelling [Completed]
To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Validation of 18F-MISO-PET and 18F-FLT-PET [Terminated]
Hypoxia and tumor cell proliferation are important mechanisms contributing to resistance to radiotherapy in human head and neck tumor cells. Currently, assessment of these two tumor characteristics is performed in biopsies using immunohistochemical staining and subsequent analysis. A promising non-invasive method of characterizing a tumor is the use of positron-emission tomography (PET). Specific tracers can be used to detect hypoxia and proliferative activity. 18F-misonidazole is a tracer for hypoxia and 18F-thymidine is a tracer for proliferation. Patients suffering from head and neck cancer and who will undergo surgery will be included in this study. One week before the surgery the patients will undergo a CT-scan and a PET-scan with either of the tracers. Shortly before the surgery they will be given immunohistochemically detectable marker substances enabling the characterization of the tumor samples gathered from the resection specimen. These markers are pimonidazole for detection of hypoxia and iododeoxyuridine for detection of tumor cell proliferation. The data collected by PET-scan will be analysed and compared to the results acquired by immunohistochemistry.

more trials >>


Page last updated: 2006-08-28

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015